Press Releases Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-09 pm EST			5-day change	1st Jan Change
162.26 ^USD	-3.95%		-2.67%	+31.76%

Dec. 09	Jazz Pharmaceuticals Insider Sold Shares Worth $797,783, According to a Recent SEC Filing	MT
Dec. 05	Jazz Pharmaceuticals plc to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex®? (Cannabidiol) Outcomes in Treatment-Resistant Epilepsies At the American Epilepsy Society 2025 Annual Meeting	CI

Press Releases

Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting	Dec. 05	PR
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium	Dec. 02	PR
Saniona publishes its interim report for the third quarter of 2025	Nov. 27	AQ
Jazz Pharmaceuticals : Partial Redemption of Jazz Pharmaceuticals UK Holding Limited	Nov. 20	PU
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference	Nov. 18	PR
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma	Nov. 17	PR
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025	Nov. 12	AQ
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025	Nov. 12	AQ
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025	Nov. 11	PR
Jazz Pharmaceuticals : UK Holdings Limited - 4.6% Fixed Rate Note due 15 January 2029 - 2025 Financial Results - Q3 Results and Updates 2025 Financial Guidance	Nov. 06	PU
Jazz Pharmaceuticals : 3Q25 Earnings Presentation FINAL	Nov. 05	PU
Jazz: Q3 Earnings Snapshot	Nov. 05	AQ
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance	Nov. 05	PR
Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors	Oct. 28	PR
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025	Oct. 22	PR
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer	Oct. 22	AQ
Jazz Pharmaceuticals plc - FDA Approves Zepzelca and Atezolizumab Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer	Oct. 03	AQ
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer	Oct. 02	PR
EClinical Solutions Explores Data Intelligence in Modern Clinical Trials at ENGAGE 2025	Sep. 26	AQ
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses	Sep. 22	PR
Jazz Pharmaceuticals plc - Modeyso Included in National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma	Sep. 10	AQ
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma	Sep. 09	PR
Saniona publishes its interim report for the second quarter of 2025	Aug. 28	AQ
Jazz Pharmaceuticals : Dordaviprone Launch Call FINAL	Aug. 27	PU
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference	Aug. 21	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Press Releases

Filters